Abbott pays billions to get Latin American presence

The company is buying Chile's CFR Pharmaceuticals, and says the deal will add about $900 million to its sales next year.

By MSN Money Partner May 16, 2014 3:26PM
A stent inspection at Abbott Vascular’s manufacturing plant
© Abbott LaboratoriesBy Laura Lorenzetti, Fortune

Abbott Laboratories (ABT), the largest maker of heart stents and nutritional drinks such as Pedialyte and Ensure, has agreed to buy Chile's CFR Pharmaceuticals for $2.9 billion, adding to the dealmaking spreading through the health care industry.


The purchase will expand Abbott's reach in the $73 billion Latin American pharmaceutical industry and more than double its presence within branded generic drugs, the company said


The Latin American pharma market is estimated to grow two to three times faster than developed markets over the coming years and reach $124 billion by 2018, according to IMS forecasts.


"The acquisition will significantly enhance and broaden Abbott's Latin American footprint," said Miles White, chairman and CEO of Abbott. "And is well aligned with our long-term strategy and commitment to fast-growing markets."


Abbott will acquire the holding company that owns 73 percent of CFR and will complete a cash tender offer for the remaining shares. The Illinois-based drug maker will assume about $430 million in debt to get the deal done.


The acquisition, which establishes Abbott as one of the top 10 pharma companies in Latin America, is expected to add about $900 million to the drug-maker's sales in 2015, with expected double-digit sales growth over the next several years. Abbott hasn't changed its full-year guidance and said the purchase will not affect ongoing earnings-per-share expectations.


More from Fortune


Tags: ABT
1Comment
May 18, 2014 4:44PM
avatar
So where are all those writers claiming Abbott is going to spin off it's generic drug business?
Report
Please help us to maintain a healthy and vibrant community by reporting any illegal or inappropriate behavior. If you believe a message violates theCode of Conductplease use this form to notify the moderators. They will investigate your report and take appropriate action. If necessary, they report all illegal activity to the proper authorities.
Categories
100 character limit
Are you sure you want to delete this comment?

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

STOCK SCOUTER

StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

120
120 rated 1
268
268 rated 2
439
439 rated 3
709
709 rated 4
641
641 rated 5
609
609 rated 6
640
640 rated 7
516
516 rated 8
272
272 rated 9
152
152 rated 10
12345678910

Top Picks

SYMBOLNAMERATING
EXCEXELON CORPORATION10
TAT&T Inc9
VZVERIZON COMMUNICATIONS8
CTLCENTURYLINK Inc8
AAPLAPPLE Inc10
More

VIDEO ON MSN MONEY

ABOUT

Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.